ASCO Proposes Overhaul of Medicare’s Oncology Payment System

Article

Medicare’s payment system for cancer care services should be restructured to focus on value over volume and offer incentives for providing high-quality, patient-centered care.

Medicare’s payment system for cancer care services should be restructured to focus on value over volume and offer incentives for providing high-quality, patient-centered care, according to a new proposal from the American Society of Clinical Oncology (ASCO).

“The current Medicare physician payment system does not recognize cognitive-based services nor does it reimburse for critical patient support services that practices provide, such as nutritional guidance and symptom management,” says ASCO president-elect Peter Yu, MD, in an ASCO news release. “At the same time, soaring healthcare costs are creating untenable instability in the cancer community.”

The proposal, “Consolidated Payments for Oncology: Payment Reform to Support Patient-Centered Care for Cancer,” notes that the current system pays oncologists only for in-person office visits and medication administration but not for other essential services, such as phone and email communication with patients, counseling services, and managing oral medications. Under the proposal, oncologists would receive five types of monthly payments based on stage of treatment: new patient visits; active treatment; active monitoring; transition of treatment; and clinical trial.

In addition to the five bundled monthly payments, oncologists would continue to receive separate payments for tests and major procedures and reimbursement for drugs for administration. The proposal is intended as a model that can be customized to accommodate individual practices of different sizes and demographics.

“We believe we have identified the essential elements of what a patient-centered, oncology-specific payment system should look like,” said Jeffrey Ward, MD, chair of ASCO’s payment reform workgroup. “Additional piloting by oncology practices will help identify specific strengths and weaknesses in our proposal to guide further refinements going forward.”

The proposal will improve patient care and practice operations in several key ways, according to ASCO:

• Coordinated patient-centered care. Oncologists would have the flexibility and resources they need to deliver high-quality care at an affordable cost.

• Simpler billing structure. The number of billing codes would be cut from 58 to 11, reducing administrative burdens and simplifying cost-sharing.

• Predictable revenues. Practices would receive more predictable monthly payments and be less dependent on revenue from infusion chemotherapy.

• Accountability. Practices that meet national standards for quality would receive up to 10% higher payments while payments would be cut by 10% for those that do not deliver recommended care.

ASCO called on Congress to consider the proposal as a new model for oncology payments under Medicare reform. The group has posted the complete text of the proposal online and is soliciting comments.

“We encourage every oncologist in this country to review and provide feedback on our proposal,” says Yu. “Each one of us has a vitally important responsibility to help shape future cancer care in America, and this effort plays a key role.”

Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content